nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCC5—Cisplatin—esophageal cancer	0.213	0.682	CbGbCtD
Dipyridamole—ABCB1—esophageal cancer	0.199	1	CbGaD
Dipyridamole—ABCC4—Methotrexate—esophageal cancer	0.0664	0.213	CbGbCtD
Dipyridamole—ADA—pleura—esophageal cancer	0.0242	0.164	CbGeAlD
Dipyridamole—ABCB1—Cisplatin—esophageal cancer	0.0198	0.0636	CbGbCtD
Dipyridamole—PDE8B—larynx—esophageal cancer	0.0151	0.102	CbGeAlD
Dipyridamole—Coronary heart disease—Cisplatin—esophageal cancer	0.0141	0.145	CcSEcCtD
Dipyridamole—ABCB1—Methotrexate—esophageal cancer	0.0129	0.0413	CbGbCtD
Dipyridamole—PRUNE—bronchus—esophageal cancer	0.00488	0.0331	CbGeAlD
Dipyridamole—PDE6D—bronchus—esophageal cancer	0.00471	0.032	CbGeAlD
Dipyridamole—PDE11A—epithelium—esophageal cancer	0.00438	0.0297	CbGeAlD
Dipyridamole—Abdominal distress—Methotrexate—esophageal cancer	0.00413	0.0423	CcSEcCtD
Dipyridamole—PDE8B—neck—esophageal cancer	0.00399	0.0271	CbGeAlD
Dipyridamole—PDE1C—lung—esophageal cancer	0.00349	0.0237	CbGeAlD
Dipyridamole—PRUNE—lung—esophageal cancer	0.00315	0.0214	CbGeAlD
Dipyridamole—PDE6D—lung—esophageal cancer	0.00304	0.0206	CbGeAlD
Dipyridamole—PDE6B—lung—esophageal cancer	0.00299	0.0203	CbGeAlD
Dipyridamole—PDE6G—lung—esophageal cancer	0.00268	0.0182	CbGeAlD
Dipyridamole—PDE8B—bronchus—esophageal cancer	0.00267	0.0181	CbGeAlD
Dipyridamole—Coronary artery disease—Cisplatin—esophageal cancer	0.00257	0.0264	CcSEcCtD
Dipyridamole—PDE2A—trachea—esophageal cancer	0.00252	0.0171	CbGeAlD
Dipyridamole—PDE8A—bronchus—esophageal cancer	0.00241	0.0163	CbGeAlD
Dipyridamole—PDE1C—lymph node—esophageal cancer	0.00239	0.0162	CbGeAlD
Dipyridamole—PDE8A—smooth muscle tissue—esophageal cancer	0.00235	0.016	CbGeAlD
Dipyridamole—PDE1A—smooth muscle tissue—esophageal cancer	0.00228	0.0154	CbGeAlD
Dipyridamole—PDE7B—lung—esophageal cancer	0.00217	0.0147	CbGeAlD
Dipyridamole—PDE10A—digestive system—esophageal cancer	0.00217	0.0147	CbGeAlD
Dipyridamole—PDE8A—trachea—esophageal cancer	0.00216	0.0146	CbGeAlD
Dipyridamole—PRUNE—lymph node—esophageal cancer	0.00215	0.0146	CbGeAlD
Dipyridamole—PDE6D—lymph node—esophageal cancer	0.00208	0.0141	CbGeAlD
Dipyridamole—PDE6G—lymph node—esophageal cancer	0.00183	0.0124	CbGeAlD
Dipyridamole—PDE2A—lung—esophageal cancer	0.00181	0.0123	CbGeAlD
Dipyridamole—PDE10A—lung—esophageal cancer	0.00181	0.0123	CbGeAlD
Dipyridamole—PDE8B—lung—esophageal cancer	0.00173	0.0117	CbGeAlD
Dipyridamole—PDE3B—lung—esophageal cancer	0.00169	0.0114	CbGeAlD
Dipyridamole—PDE5A—epithelium—esophageal cancer	0.00167	0.0113	CbGeAlD
Dipyridamole—PDE5A—smooth muscle tissue—esophageal cancer	0.0016	0.0109	CbGeAlD
Dipyridamole—Proctalgia—Capecitabine—esophageal cancer	0.0016	0.0164	CcSEcCtD
Dipyridamole—PDE3A—smooth muscle tissue—esophageal cancer	0.00156	0.0106	CbGeAlD
Dipyridamole—PDE8A—lung—esophageal cancer	0.00155	0.0105	CbGeAlD
Dipyridamole—ADA—digestive system—esophageal cancer	0.00153	0.0104	CbGeAlD
Dipyridamole—PDE1A—lung—esophageal cancer	0.0015	0.0102	CbGeAlD
Dipyridamole—ABCC5—bronchus—esophageal cancer	0.0015	0.0102	CbGeAlD
Dipyridamole—Transient ischaemic attack—Capecitabine—esophageal cancer	0.00149	0.0152	CcSEcCtD
Dipyridamole—PDE7B—lymph node—esophageal cancer	0.00148	0.0101	CbGeAlD
Dipyridamole—Cardiomyopathy—Capecitabine—esophageal cancer	0.00147	0.015	CcSEcCtD
Dipyridamole—SLC29A1—bronchus—esophageal cancer	0.00138	0.00934	CbGeAlD
Dipyridamole—ADA—lung—esophageal cancer	0.00128	0.00866	CbGeAlD
Dipyridamole—PDE5A—digestive system—esophageal cancer	0.00127	0.00859	CbGeAlD
Dipyridamole—PDE4A—lung—esophageal cancer	0.00124	0.00844	CbGeAlD
Dipyridamole—PDE2A—lymph node—esophageal cancer	0.00124	0.00839	CbGeAlD
Dipyridamole—PDE10A—lymph node—esophageal cancer	0.00124	0.00839	CbGeAlD
Dipyridamole—SLC29A1—trachea—esophageal cancer	0.00124	0.00839	CbGeAlD
Dipyridamole—PDE1B—lymph node—esophageal cancer	0.00123	0.00831	CbGeAlD
Dipyridamole—PDE8B—lymph node—esophageal cancer	0.00118	0.008	CbGeAlD
Dipyridamole—PDE3B—lymph node—esophageal cancer	0.00115	0.00782	CbGeAlD
Dipyridamole—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.00114	0.0117	CcSEcCtD
Dipyridamole—SLC29A1—digestive system—esophageal cancer	0.00106	0.00722	CbGeAlD
Dipyridamole—PDE8A—lymph node—esophageal cancer	0.00106	0.0072	CbGeAlD
Dipyridamole—Pain—Carboplatin—esophageal cancer	0.00106	0.0109	CcSEcCtD
Dipyridamole—PDE5A—lung—esophageal cancer	0.00106	0.00718	CbGeAlD
Dipyridamole—ABCC4—bronchus—esophageal cancer	0.00104	0.00705	CbGeAlD
Dipyridamole—PDE3A—lung—esophageal cancer	0.00103	0.00698	CbGeAlD
Dipyridamole—PDE1A—lymph node—esophageal cancer	0.00103	0.00697	CbGeAlD
Dipyridamole—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00098	0.01	CcSEcCtD
Dipyridamole—ABCC5—lung—esophageal cancer	0.000968	0.00656	CbGeAlD
Dipyridamole—Injection site pain—Capecitabine—esophageal cancer	0.000919	0.00943	CcSEcCtD
Dipyridamole—Rigors—Capecitabine—esophageal cancer	0.000919	0.00943	CcSEcCtD
Dipyridamole—Dysphonia—Capecitabine—esophageal cancer	0.000912	0.00935	CcSEcCtD
Dipyridamole—Extrasystoles—Capecitabine—esophageal cancer	0.000892	0.00915	CcSEcCtD
Dipyridamole—SLC29A1—lung—esophageal cancer	0.000889	0.00603	CbGeAlD
Dipyridamole—ADA—lymph node—esophageal cancer	0.000873	0.00592	CbGeAlD
Dipyridamole—PDE4A—lymph node—esophageal cancer	0.000851	0.00577	CbGeAlD
Dipyridamole—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.000831	0.00852	CcSEcCtD
Dipyridamole—ABCC4—digestive system—esophageal cancer	0.000803	0.00545	CbGeAlD
Dipyridamole—Coordination abnormal—Capecitabine—esophageal cancer	0.000764	0.00784	CcSEcCtD
Dipyridamole—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000763	0.00783	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000754	0.00773	CcSEcCtD
Dipyridamole—Injection site reaction—Capecitabine—esophageal cancer	0.000746	0.00765	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000739	0.00758	CcSEcCtD
Dipyridamole—PDE5A—lymph node—esophageal cancer	0.000724	0.00491	CbGeAlD
Dipyridamole—PDE3A—lymph node—esophageal cancer	0.000704	0.00477	CbGeAlD
Dipyridamole—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000675	0.00692	CcSEcCtD
Dipyridamole—ABCC4—lung—esophageal cancer	0.000671	0.00455	CbGeAlD
Dipyridamole—Cramp muscle—Cisplatin—esophageal cancer	0.000665	0.00682	CcSEcCtD
Dipyridamole—ABCC5—lymph node—esophageal cancer	0.000662	0.00449	CbGeAlD
Dipyridamole—Ear pain—Capecitabine—esophageal cancer	0.000638	0.00655	CcSEcCtD
Dipyridamole—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000623	0.00639	CcSEcCtD
Dipyridamole—Sweating increased—Cisplatin—esophageal cancer	0.000622	0.00638	CcSEcCtD
Dipyridamole—Bone disorder—Methotrexate—esophageal cancer	0.000618	0.00634	CcSEcCtD
Dipyridamole—Abdominal discomfort—Cisplatin—esophageal cancer	0.000612	0.00628	CcSEcCtD
Dipyridamole—SLC29A1—lymph node—esophageal cancer	0.000608	0.00412	CbGeAlD
Dipyridamole—Eye pain—Capecitabine—esophageal cancer	0.000603	0.00619	CcSEcCtD
Dipyridamole—Hot flush—Capecitabine—esophageal cancer	0.000582	0.00597	CcSEcCtD
Dipyridamole—Increased appetite—Capecitabine—esophageal cancer	0.00058	0.00595	CcSEcCtD
Dipyridamole—Menopausal symptoms—Capecitabine—esophageal cancer	0.000577	0.00592	CcSEcCtD
Dipyridamole—Atrial fibrillation—Capecitabine—esophageal cancer	0.000575	0.0059	CcSEcCtD
Dipyridamole—Thirst—Capecitabine—esophageal cancer	0.000572	0.00587	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000561	0.00576	CcSEcCtD
Dipyridamole—Arthritis—Capecitabine—esophageal cancer	0.00056	0.00575	CcSEcCtD
Dipyridamole—Myocardial infarction—Cisplatin—esophageal cancer	0.000558	0.00572	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000556	0.0057	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000545	0.00559	CcSEcCtD
Dipyridamole—Migraine—Capecitabine—esophageal cancer	0.000536	0.0055	CcSEcCtD
Dipyridamole—Bradycardia—Cisplatin—esophageal cancer	0.00052	0.00534	CcSEcCtD
Dipyridamole—Cardiac arrest—Capecitabine—esophageal cancer	0.000518	0.00531	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000497	0.0051	CcSEcCtD
Dipyridamole—Abdominal pain upper—Capecitabine—esophageal cancer	0.000497	0.0051	CcSEcCtD
Dipyridamole—Pulmonary oedema—Methotrexate—esophageal cancer	0.000497	0.0051	CcSEcCtD
Dipyridamole—Tinnitus—Cisplatin—esophageal cancer	0.000477	0.00489	CcSEcCtD
Dipyridamole—Cardiac disorder—Cisplatin—esophageal cancer	0.000474	0.00487	CcSEcCtD
Dipyridamole—Flushing—Cisplatin—esophageal cancer	0.000474	0.00487	CcSEcCtD
Dipyridamole—Dysphagia—Capecitabine—esophageal cancer	0.000471	0.00483	CcSEcCtD
Dipyridamole—Bronchospasm—Capecitabine—esophageal cancer	0.000463	0.00475	CcSEcCtD
Dipyridamole—Immune system disorder—Cisplatin—esophageal cancer	0.000462	0.00474	CcSEcCtD
Dipyridamole—Mediastinal disorder—Cisplatin—esophageal cancer	0.000461	0.00472	CcSEcCtD
Dipyridamole—ABCC4—lymph node—esophageal cancer	0.000459	0.00311	CbGeAlD
Dipyridamole—Angina pectoris—Capecitabine—esophageal cancer	0.000458	0.0047	CcSEcCtD
Dipyridamole—Sweating increased—Capecitabine—esophageal cancer	0.000458	0.0047	CcSEcCtD
Dipyridamole—Arrhythmia—Cisplatin—esophageal cancer	0.000457	0.00468	CcSEcCtD
Dipyridamole—Alopecia—Cisplatin—esophageal cancer	0.000452	0.00463	CcSEcCtD
Dipyridamole—Abdominal discomfort—Capecitabine—esophageal cancer	0.000451	0.00463	CcSEcCtD
Dipyridamole—Flatulence—Cisplatin—esophageal cancer	0.000438	0.0045	CcSEcCtD
Dipyridamole—Muscle spasms—Cisplatin—esophageal cancer	0.000428	0.00439	CcSEcCtD
Dipyridamole—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000419	0.0043	CcSEcCtD
Dipyridamole—Tremor—Cisplatin—esophageal cancer	0.000417	0.00428	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000414	0.00424	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000414	0.00424	CcSEcCtD
Dipyridamole—Ill-defined disorder—Cisplatin—esophageal cancer	0.000413	0.00423	CcSEcCtD
Dipyridamole—Myocardial infarction—Capecitabine—esophageal cancer	0.000411	0.00422	CcSEcCtD
Dipyridamole—Anaemia—Cisplatin—esophageal cancer	0.000411	0.00422	CcSEcCtD
Dipyridamole—Malaise—Cisplatin—esophageal cancer	0.000401	0.00412	CcSEcCtD
Dipyridamole—Convulsion—Cisplatin—esophageal cancer	0.000385	0.00395	CcSEcCtD
Dipyridamole—Bradycardia—Capecitabine—esophageal cancer	0.000384	0.00393	CcSEcCtD
Dipyridamole—Myalgia—Cisplatin—esophageal cancer	0.000379	0.00389	CcSEcCtD
Dipyridamole—Haemoglobin—Capecitabine—esophageal cancer	0.000379	0.00388	CcSEcCtD
Dipyridamole—Rhinitis—Capecitabine—esophageal cancer	0.000378	0.00387	CcSEcCtD
Dipyridamole—Anxiety—Cisplatin—esophageal cancer	0.000377	0.00387	CcSEcCtD
Dipyridamole—Haemorrhage—Capecitabine—esophageal cancer	0.000377	0.00386	CcSEcCtD
Dipyridamole—Hepatitis—Capecitabine—esophageal cancer	0.000377	0.00386	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000376	0.00386	CcSEcCtD
Dipyridamole—Hypoaesthesia—Capecitabine—esophageal cancer	0.000375	0.00385	CcSEcCtD
Dipyridamole—Discomfort—Cisplatin—esophageal cancer	0.000374	0.00384	CcSEcCtD
Dipyridamole—Pharyngitis—Capecitabine—esophageal cancer	0.000374	0.00384	CcSEcCtD
Dipyridamole—ABCB1—epithelium—esophageal cancer	0.000368	0.00249	CbGeAlD
Dipyridamole—Anaphylactic shock—Cisplatin—esophageal cancer	0.000363	0.00372	CcSEcCtD
Dipyridamole—Oedema—Cisplatin—esophageal cancer	0.000363	0.00372	CcSEcCtD
Dipyridamole—Nervous system disorder—Cisplatin—esophageal cancer	0.000356	0.00365	CcSEcCtD
Dipyridamole—Thrombocytopenia—Cisplatin—esophageal cancer	0.000356	0.00365	CcSEcCtD
Dipyridamole—Tachycardia—Cisplatin—esophageal cancer	0.000354	0.00364	CcSEcCtD
Dipyridamole—Skin disorder—Cisplatin—esophageal cancer	0.000353	0.00362	CcSEcCtD
Dipyridamole—Tinnitus—Capecitabine—esophageal cancer	0.000351	0.0036	CcSEcCtD
Dipyridamole—Hyperhidrosis—Cisplatin—esophageal cancer	0.000351	0.0036	CcSEcCtD
Dipyridamole—Flushing—Capecitabine—esophageal cancer	0.00035	0.00359	CcSEcCtD
Dipyridamole—Cardiac disorder—Capecitabine—esophageal cancer	0.00035	0.00359	CcSEcCtD
Dipyridamole—Angiopathy—Capecitabine—esophageal cancer	0.000342	0.00351	CcSEcCtD
Dipyridamole—Immune system disorder—Capecitabine—esophageal cancer	0.00034	0.00349	CcSEcCtD
Dipyridamole—Mediastinal disorder—Capecitabine—esophageal cancer	0.00034	0.00348	CcSEcCtD
Dipyridamole—Hypotension—Cisplatin—esophageal cancer	0.000339	0.00348	CcSEcCtD
Dipyridamole—Chills—Capecitabine—esophageal cancer	0.000338	0.00347	CcSEcCtD
Dipyridamole—Arrhythmia—Capecitabine—esophageal cancer	0.000337	0.00345	CcSEcCtD
Dipyridamole—Abdominal discomfort—Methotrexate—esophageal cancer	0.000336	0.00345	CcSEcCtD
Dipyridamole—Alopecia—Capecitabine—esophageal cancer	0.000333	0.00342	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000331	0.00339	CcSEcCtD
Dipyridamole—Paraesthesia—Cisplatin—esophageal cancer	0.000326	0.00334	CcSEcCtD
Dipyridamole—ABCB1—trachea—esophageal cancer	0.000325	0.0022	CbGeAlD
Dipyridamole—Dyspnoea—Cisplatin—esophageal cancer	0.000324	0.00332	CcSEcCtD
Dipyridamole—Flatulence—Capecitabine—esophageal cancer	0.000323	0.00332	CcSEcCtD
Dipyridamole—Dysgeusia—Capecitabine—esophageal cancer	0.000321	0.00329	CcSEcCtD
Dipyridamole—Back pain—Capecitabine—esophageal cancer	0.000317	0.00325	CcSEcCtD
Dipyridamole—Muscle spasms—Capecitabine—esophageal cancer	0.000315	0.00323	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000313	0.00322	CcSEcCtD
Dipyridamole—Pain—Cisplatin—esophageal cancer	0.000311	0.00319	CcSEcCtD
Dipyridamole—Tremor—Capecitabine—esophageal cancer	0.000307	0.00315	CcSEcCtD
Dipyridamole—Ill-defined disorder—Capecitabine—esophageal cancer	0.000304	0.00312	CcSEcCtD
Dipyridamole—Anaemia—Capecitabine—esophageal cancer	0.000303	0.00311	CcSEcCtD
Dipyridamole—Feeling abnormal—Cisplatin—esophageal cancer	0.000299	0.00307	CcSEcCtD
Dipyridamole—Malaise—Capecitabine—esophageal cancer	0.000296	0.00303	CcSEcCtD
Dipyridamole—Vertigo—Capecitabine—esophageal cancer	0.000295	0.00302	CcSEcCtD
Dipyridamole—Syncope—Capecitabine—esophageal cancer	0.000294	0.00302	CcSEcCtD
Dipyridamole—Palpitations—Capecitabine—esophageal cancer	0.00029	0.00297	CcSEcCtD
Dipyridamole—Loss of consciousness—Capecitabine—esophageal cancer	0.000288	0.00296	CcSEcCtD
Dipyridamole—Cough—Capecitabine—esophageal cancer	0.000286	0.00294	CcSEcCtD
Dipyridamole—Hypertension—Capecitabine—esophageal cancer	0.000283	0.0029	CcSEcCtD
Dipyridamole—Haemoglobin—Methotrexate—esophageal cancer	0.000282	0.00289	CcSEcCtD
Dipyridamole—Hepatitis—Methotrexate—esophageal cancer	0.00028	0.00288	CcSEcCtD
Dipyridamole—Haemorrhage—Methotrexate—esophageal cancer	0.00028	0.00288	CcSEcCtD
Dipyridamole—ABCB1—digestive system—esophageal cancer	0.00028	0.0019	CbGeAlD
Dipyridamole—Arthralgia—Capecitabine—esophageal cancer	0.000279	0.00286	CcSEcCtD
Dipyridamole—Chest pain—Capecitabine—esophageal cancer	0.000279	0.00286	CcSEcCtD
Dipyridamole—Myalgia—Capecitabine—esophageal cancer	0.000279	0.00286	CcSEcCtD
Dipyridamole—Pharyngitis—Methotrexate—esophageal cancer	0.000278	0.00286	CcSEcCtD
Dipyridamole—Anxiety—Capecitabine—esophageal cancer	0.000278	0.00285	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000277	0.00284	CcSEcCtD
Dipyridamole—Discomfort—Capecitabine—esophageal cancer	0.000276	0.00283	CcSEcCtD
Dipyridamole—Dry mouth—Capecitabine—esophageal cancer	0.000273	0.0028	CcSEcCtD
Dipyridamole—Oedema—Capecitabine—esophageal cancer	0.000268	0.00275	CcSEcCtD
Dipyridamole—Hypersensitivity—Cisplatin—esophageal cancer	0.000268	0.00274	CcSEcCtD
Dipyridamole—Shock—Capecitabine—esophageal cancer	0.000263	0.0027	CcSEcCtD
Dipyridamole—Nervous system disorder—Capecitabine—esophageal cancer	0.000262	0.00269	CcSEcCtD
Dipyridamole—Thrombocytopenia—Capecitabine—esophageal cancer	0.000262	0.00269	CcSEcCtD
Dipyridamole—Tinnitus—Methotrexate—esophageal cancer	0.000261	0.00268	CcSEcCtD
Dipyridamole—Tachycardia—Capecitabine—esophageal cancer	0.000261	0.00268	CcSEcCtD
Dipyridamole—Asthenia—Cisplatin—esophageal cancer	0.000261	0.00267	CcSEcCtD
Dipyridamole—Cardiac disorder—Methotrexate—esophageal cancer	0.00026	0.00267	CcSEcCtD
Dipyridamole—Skin disorder—Capecitabine—esophageal cancer	0.00026	0.00267	CcSEcCtD
Dipyridamole—Hyperhidrosis—Capecitabine—esophageal cancer	0.000259	0.00265	CcSEcCtD
Dipyridamole—Angiopathy—Methotrexate—esophageal cancer	0.000254	0.00261	CcSEcCtD
Dipyridamole—Immune system disorder—Methotrexate—esophageal cancer	0.000253	0.0026	CcSEcCtD
Dipyridamole—Mediastinal disorder—Methotrexate—esophageal cancer	0.000253	0.00259	CcSEcCtD
Dipyridamole—Chills—Methotrexate—esophageal cancer	0.000252	0.00258	CcSEcCtD
Dipyridamole—Hypotension—Capecitabine—esophageal cancer	0.00025	0.00257	CcSEcCtD
Dipyridamole—Diarrhoea—Cisplatin—esophageal cancer	0.000248	0.00255	CcSEcCtD
Dipyridamole—Alopecia—Methotrexate—esophageal cancer	0.000248	0.00254	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000244	0.0025	CcSEcCtD
Dipyridamole—Paraesthesia—Capecitabine—esophageal cancer	0.00024	0.00247	CcSEcCtD
Dipyridamole—Dysgeusia—Methotrexate—esophageal cancer	0.000239	0.00245	CcSEcCtD
Dipyridamole—Dyspnoea—Capecitabine—esophageal cancer	0.000239	0.00245	CcSEcCtD
Dipyridamole—Back pain—Methotrexate—esophageal cancer	0.000236	0.00242	CcSEcCtD
Dipyridamole—Dyspepsia—Capecitabine—esophageal cancer	0.000236	0.00242	CcSEcCtD
Dipyridamole—ABCB1—lung—esophageal cancer	0.000234	0.00158	CbGeAlD
Dipyridamole—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000231	0.00237	CcSEcCtD
Dipyridamole—Vomiting—Cisplatin—esophageal cancer	0.000231	0.00237	CcSEcCtD
Dipyridamole—Fatigue—Capecitabine—esophageal cancer	0.000231	0.00237	CcSEcCtD
Dipyridamole—Rash—Cisplatin—esophageal cancer	0.000229	0.00235	CcSEcCtD
Dipyridamole—Pain—Capecitabine—esophageal cancer	0.000229	0.00235	CcSEcCtD
Dipyridamole—Dermatitis—Cisplatin—esophageal cancer	0.000229	0.00235	CcSEcCtD
Dipyridamole—Ill-defined disorder—Methotrexate—esophageal cancer	0.000227	0.00232	CcSEcCtD
Dipyridamole—Anaemia—Methotrexate—esophageal cancer	0.000226	0.00231	CcSEcCtD
Dipyridamole—Feeling abnormal—Capecitabine—esophageal cancer	0.000221	0.00226	CcSEcCtD
Dipyridamole—Malaise—Methotrexate—esophageal cancer	0.00022	0.00226	CcSEcCtD
Dipyridamole—Vertigo—Methotrexate—esophageal cancer	0.000219	0.00225	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000219	0.00225	CcSEcCtD
Dipyridamole—Nausea—Cisplatin—esophageal cancer	0.000216	0.00221	CcSEcCtD
Dipyridamole—Cough—Methotrexate—esophageal cancer	0.000213	0.00219	CcSEcCtD
Dipyridamole—Urticaria—Capecitabine—esophageal cancer	0.000213	0.00218	CcSEcCtD
Dipyridamole—Abdominal pain—Capecitabine—esophageal cancer	0.000212	0.00217	CcSEcCtD
Dipyridamole—Convulsion—Methotrexate—esophageal cancer	0.000212	0.00217	CcSEcCtD
Dipyridamole—Arthralgia—Methotrexate—esophageal cancer	0.000208	0.00213	CcSEcCtD
Dipyridamole—Chest pain—Methotrexate—esophageal cancer	0.000208	0.00213	CcSEcCtD
Dipyridamole—Myalgia—Methotrexate—esophageal cancer	0.000208	0.00213	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000206	0.00212	CcSEcCtD
Dipyridamole—Discomfort—Methotrexate—esophageal cancer	0.000205	0.00211	CcSEcCtD
Dipyridamole—Anaphylactic shock—Methotrexate—esophageal cancer	0.000199	0.00204	CcSEcCtD
Dipyridamole—Hypersensitivity—Capecitabine—esophageal cancer	0.000197	0.00202	CcSEcCtD
Dipyridamole—Nervous system disorder—Methotrexate—esophageal cancer	0.000195	0.002	CcSEcCtD
Dipyridamole—Thrombocytopenia—Methotrexate—esophageal cancer	0.000195	0.002	CcSEcCtD
Dipyridamole—Skin disorder—Methotrexate—esophageal cancer	0.000194	0.00199	CcSEcCtD
Dipyridamole—Hyperhidrosis—Methotrexate—esophageal cancer	0.000193	0.00198	CcSEcCtD
Dipyridamole—Asthenia—Capecitabine—esophageal cancer	0.000192	0.00197	CcSEcCtD
Dipyridamole—Pruritus—Capecitabine—esophageal cancer	0.000189	0.00194	CcSEcCtD
Dipyridamole—Hypotension—Methotrexate—esophageal cancer	0.000186	0.00191	CcSEcCtD
Dipyridamole—Diarrhoea—Capecitabine—esophageal cancer	0.000183	0.00188	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000182	0.00186	CcSEcCtD
Dipyridamole—Paraesthesia—Methotrexate—esophageal cancer	0.000179	0.00184	CcSEcCtD
Dipyridamole—Dyspnoea—Methotrexate—esophageal cancer	0.000178	0.00182	CcSEcCtD
Dipyridamole—Somnolence—Methotrexate—esophageal cancer	0.000177	0.00182	CcSEcCtD
Dipyridamole—Dizziness—Capecitabine—esophageal cancer	0.000177	0.00182	CcSEcCtD
Dipyridamole—Dyspepsia—Methotrexate—esophageal cancer	0.000175	0.0018	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000172	0.00176	CcSEcCtD
Dipyridamole—Fatigue—Methotrexate—esophageal cancer	0.000172	0.00176	CcSEcCtD
Dipyridamole—Pain—Methotrexate—esophageal cancer	0.00017	0.00175	CcSEcCtD
Dipyridamole—Vomiting—Capecitabine—esophageal cancer	0.00017	0.00175	CcSEcCtD
Dipyridamole—Rash—Capecitabine—esophageal cancer	0.000169	0.00173	CcSEcCtD
Dipyridamole—Dermatitis—Capecitabine—esophageal cancer	0.000169	0.00173	CcSEcCtD
Dipyridamole—Headache—Capecitabine—esophageal cancer	0.000168	0.00172	CcSEcCtD
Dipyridamole—Feeling abnormal—Methotrexate—esophageal cancer	0.000164	0.00168	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000163	0.00167	CcSEcCtD
Dipyridamole—ABCB1—lymph node—esophageal cancer	0.00016	0.00108	CbGeAlD
Dipyridamole—Nausea—Capecitabine—esophageal cancer	0.000159	0.00163	CcSEcCtD
Dipyridamole—Urticaria—Methotrexate—esophageal cancer	0.000158	0.00162	CcSEcCtD
Dipyridamole—Abdominal pain—Methotrexate—esophageal cancer	0.000158	0.00162	CcSEcCtD
Dipyridamole—Hypersensitivity—Methotrexate—esophageal cancer	0.000147	0.00151	CcSEcCtD
Dipyridamole—Asthenia—Methotrexate—esophageal cancer	0.000143	0.00147	CcSEcCtD
Dipyridamole—Pruritus—Methotrexate—esophageal cancer	0.000141	0.00145	CcSEcCtD
Dipyridamole—Diarrhoea—Methotrexate—esophageal cancer	0.000136	0.0014	CcSEcCtD
Dipyridamole—Dizziness—Methotrexate—esophageal cancer	0.000132	0.00135	CcSEcCtD
Dipyridamole—Vomiting—Methotrexate—esophageal cancer	0.000127	0.0013	CcSEcCtD
Dipyridamole—Rash—Methotrexate—esophageal cancer	0.000126	0.00129	CcSEcCtD
Dipyridamole—Dermatitis—Methotrexate—esophageal cancer	0.000126	0.00129	CcSEcCtD
Dipyridamole—Headache—Methotrexate—esophageal cancer	0.000125	0.00128	CcSEcCtD
Dipyridamole—Nausea—Methotrexate—esophageal cancer	0.000118	0.00121	CcSEcCtD
Dipyridamole—PDE10A—Signaling by GPCR—PIK3CA—esophageal cancer	1.85e-05	7.57e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—EGFR—esophageal cancer	1.84e-05	7.55e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—TP53—esophageal cancer	1.83e-05	7.52e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	1.83e-05	7.49e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—ERBB2—esophageal cancer	1.81e-05	7.43e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CA1—esophageal cancer	1.8e-05	7.37e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC10A2—esophageal cancer	1.8e-05	7.37e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—CCND1—esophageal cancer	1.8e-05	7.36e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—CCND1—esophageal cancer	1.8e-05	7.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SMAD4—esophageal cancer	1.79e-05	7.35e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—PIK3CA—esophageal cancer	1.78e-05	7.3e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—EP300—esophageal cancer	1.78e-05	7.29e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	1.77e-05	7.28e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—NOS3—esophageal cancer	1.77e-05	7.24e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—PIK3CA—esophageal cancer	1.75e-05	7.19e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NOS2—esophageal cancer	1.74e-05	7.15e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—MYC—esophageal cancer	1.74e-05	7.13e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—MYC—esophageal cancer	1.74e-05	7.13e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—CDKN1A—esophageal cancer	1.74e-05	7.12e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—CDKN1A—esophageal cancer	1.74e-05	7.12e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—PIK3CA—esophageal cancer	1.74e-05	7.12e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—PIK3CA—esophageal cancer	1.74e-05	7.12e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.73e-05	7.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TGFBR2—esophageal cancer	1.73e-05	7.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NOTCH1—esophageal cancer	1.73e-05	7.08e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—TP53—esophageal cancer	1.72e-05	7.07e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HIF1A—esophageal cancer	1.71e-05	7.03e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—CREBBP—esophageal cancer	1.71e-05	7.02e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—CREBBP—esophageal cancer	1.71e-05	7.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CASP8—esophageal cancer	1.7e-05	6.99e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—EGFR—esophageal cancer	1.7e-05	6.97e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—EGFR—esophageal cancer	1.7e-05	6.97e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CREBBP—esophageal cancer	1.7e-05	6.95e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—MYC—esophageal cancer	1.69e-05	6.95e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—EGFR—esophageal cancer	1.69e-05	6.93e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—TP53—esophageal cancer	1.68e-05	6.88e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—TP53—esophageal cancer	1.68e-05	6.88e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—EP300—esophageal cancer	1.67e-05	6.84e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—CCND1—esophageal cancer	1.66e-05	6.83e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—EGFR—esophageal cancer	1.66e-05	6.79e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—EP300—esophageal cancer	1.65e-05	6.78e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—EP300—esophageal cancer	1.65e-05	6.78e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CA2—esophageal cancer	1.64e-05	6.74e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—CCND1—esophageal cancer	1.64e-05	6.74e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SMAD4—esophageal cancer	1.64e-05	6.73e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KDR—esophageal cancer	1.64e-05	6.72e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—PIK3CA—esophageal cancer	1.63e-05	6.68e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—PIK3CA—esophageal cancer	1.62e-05	6.64e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PTGS2—esophageal cancer	1.62e-05	6.63e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—CDKN1A—esophageal cancer	1.61e-05	6.6e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HIF1A—esophageal cancer	1.6e-05	6.58e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—PIK3CA—esophageal cancer	1.6e-05	6.58e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—CCND1—esophageal cancer	1.6e-05	6.56e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—BCL2—esophageal cancer	1.6e-05	6.55e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—PIK3CA—esophageal cancer	1.6e-05	6.55e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—CDKN1A—esophageal cancer	1.59e-05	6.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—TP53—esophageal cancer	1.58e-05	6.46e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.57e-05	6.43e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CREBBP—esophageal cancer	1.57e-05	6.42e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HIF1A—esophageal cancer	1.56e-05	6.4e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—ERBB2—esophageal cancer	1.55e-05	6.37e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—MYC—esophageal cancer	1.55e-05	6.35e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—CDKN1A—esophageal cancer	1.55e-05	6.35e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NOTCH1—esophageal cancer	1.54e-05	6.33e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KDR—esophageal cancer	1.53e-05	6.29e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—NOS3—esophageal cancer	1.53e-05	6.28e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—NOS3—esophageal cancer	1.53e-05	6.28e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—EP300—esophageal cancer	1.53e-05	6.28e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PLCE1—esophageal cancer	1.53e-05	6.27e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ADH7—esophageal cancer	1.53e-05	6.27e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.52e-05	6.22e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—EGFR—esophageal cancer	1.52e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—EP300—esophageal cancer	1.51e-05	6.2e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KDR—esophageal cancer	1.49e-05	6.12e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—PIK3CA—esophageal cancer	1.48e-05	6.05e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—PIK3CA—esophageal cancer	1.48e-05	6.05e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—EP300—esophageal cancer	1.47e-05	6.04e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HIF1A—esophageal cancer	1.47e-05	6.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—PIK3CA—esophageal cancer	1.47e-05	6.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—BCL2—esophageal cancer	1.46e-05	5.99e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NOTCH1—esophageal cancer	1.45e-05	5.93e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.44e-05	5.92e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—MYC—esophageal cancer	1.44e-05	5.91e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—MYC—esophageal cancer	1.44e-05	5.91e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—PIK3CA—esophageal cancer	1.44e-05	5.9e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—CREBBP—esophageal cancer	1.43e-05	5.88e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—ERBB2—esophageal cancer	1.43e-05	5.88e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—ERBB2—esophageal cancer	1.43e-05	5.88e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—TP53—esophageal cancer	1.43e-05	5.85e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—TP53—esophageal cancer	1.43e-05	5.85e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—ERBB2—esophageal cancer	1.42e-05	5.82e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—EGFR—esophageal cancer	1.41e-05	5.78e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—EGFR—esophageal cancer	1.41e-05	5.78e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NOTCH1—esophageal cancer	1.41e-05	5.77e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KDR—esophageal cancer	1.4e-05	5.76e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NOS3—esophageal cancer	1.4e-05	5.75e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTGS2—esophageal cancer	1.4e-05	5.75e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTGS2—esophageal cancer	1.4e-05	5.75e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CREBBP—esophageal cancer	1.4e-05	5.74e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—TP53—esophageal cancer	1.39e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—EGFR—esophageal cancer	1.38e-05	5.64e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—EP300—esophageal cancer	1.34e-05	5.51e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HIF1A—esophageal cancer	1.34e-05	5.5e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ADH1B—esophageal cancer	1.34e-05	5.5e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—MYC—esophageal cancer	1.34e-05	5.48e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—CDKN1A—esophageal cancer	1.33e-05	5.44e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NOTCH1—esophageal cancer	1.32e-05	5.42e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—MYC—esophageal cancer	1.32e-05	5.4e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—PIK3CA—esophageal cancer	1.32e-05	5.39e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.31e-05	5.39e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.31e-05	5.38e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—ERBB2—esophageal cancer	1.31e-05	5.38e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CREBBP—esophageal cancer	1.31e-05	5.37e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—EGFR—esophageal cancer	1.31e-05	5.36e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—EGFR—esophageal cancer	1.29e-05	5.28e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—EGFR—esophageal cancer	1.29e-05	5.28e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—MYC—esophageal cancer	1.28e-05	5.26e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KDR—esophageal cancer	1.28e-05	5.26e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—NOS3—esophageal cancer	1.28e-05	5.26e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTGS2—esophageal cancer	1.28e-05	5.26e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TYMP—esophageal cancer	1.28e-05	5.25e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CREBBP—esophageal cancer	1.28e-05	5.23e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—TP53—esophageal cancer	1.27e-05	5.22e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EP300—esophageal cancer	1.26e-05	5.18e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.26e-05	5.16e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—EGFR—esophageal cancer	1.26e-05	5.15e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NOS3—esophageal cancer	1.25e-05	5.14e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—EGFR—esophageal cancer	1.25e-05	5.14e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.25e-05	5.11e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—PIK3CA—esophageal cancer	1.23e-05	5.06e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.23e-05	5.05e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.23e-05	5.04e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—CDKN1A—esophageal cancer	1.23e-05	5.02e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—CDKN1A—esophageal cancer	1.23e-05	5.02e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—PIK3CA—esophageal cancer	1.22e-05	5.01e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—PIK3CA—esophageal cancer	1.22e-05	5.01e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALOX15—esophageal cancer	1.21e-05	4.98e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CDKN1A—esophageal cancer	1.21e-05	4.98e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NOTCH1—esophageal cancer	1.21e-05	4.96e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CREBBP—esophageal cancer	1.2e-05	4.92e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.2e-05	4.91e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—TP53—esophageal cancer	1.19e-05	4.9e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—PIK3CA—esophageal cancer	1.19e-05	4.9e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TP53—esophageal cancer	1.18e-05	4.85e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TP53—esophageal cancer	1.18e-05	4.85e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—EGFR—esophageal cancer	1.18e-05	4.83e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTGS2—esophageal cancer	1.17e-05	4.81e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NOS3—esophageal cancer	1.17e-05	4.81e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—ERBB2—esophageal cancer	1.17e-05	4.81e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EP300—esophageal cancer	1.17e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EP300—esophageal cancer	1.17e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTO1—esophageal cancer	1.16e-05	4.75e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TPI1—esophageal cancer	1.16e-05	4.75e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EP300—esophageal cancer	1.15e-05	4.74e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NOS3—esophageal cancer	1.14e-05	4.68e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—PIK3CA—esophageal cancer	1.13e-05	4.65e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.13e-05	4.62e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CDKN1A—esophageal cancer	1.12e-05	4.6e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—PIK3CA—esophageal cancer	1.12e-05	4.59e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—PIK3CA—esophageal cancer	1.12e-05	4.58e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALDOB—esophageal cancer	1.11e-05	4.56e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—ERBB2—esophageal cancer	1.1e-05	4.5e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TP53—esophageal cancer	1.1e-05	4.5e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CREBBP—esophageal cancer	1.1e-05	4.5e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—PIK3CA—esophageal cancer	1.09e-05	4.47e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—PIK3CA—esophageal cancer	1.09e-05	4.46e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—esophageal cancer	1.08e-05	4.44e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—EGFR—esophageal cancer	1.08e-05	4.42e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EGFR—esophageal cancer	1.08e-05	4.41e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NOS3—esophageal cancer	1.07e-05	4.4e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GAPDH—esophageal cancer	1.07e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—ERBB2—esophageal cancer	1.07e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.07e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EP300—esophageal cancer	1.07e-05	4.37e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CRABP1—esophageal cancer	1.06e-05	4.35e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—esophageal cancer	1.05e-05	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—esophageal cancer	1.04e-05	4.25e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.03e-05	4.23e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.03e-05	4.22e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.02e-05	4.19e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MYC—esophageal cancer	1.02e-05	4.17e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MYC—esophageal cancer	1.02e-05	4.17e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GNG7—esophageal cancer	1.01e-05	4.13e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ERBB2—esophageal cancer	1e-05	4.12e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1A—esophageal cancer	1e-05	4.11e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PIK3CA—esophageal cancer	9.94e-06	4.08e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EGFR—esophageal cancer	9.94e-06	4.07e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EGFR—esophageal cancer	9.94e-06	4.07e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EGFR—esophageal cancer	9.84e-06	4.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NOS3—esophageal cancer	9.82e-06	4.03e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—EP300—esophageal cancer	9.76e-06	4e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—esophageal cancer	9.7e-06	3.98e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EP300—esophageal cancer	9.53e-06	3.91e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALDH2—esophageal cancer	9.45e-06	3.87e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—esophageal cancer	9.43e-06	3.87e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1A—esophageal cancer	9.38e-06	3.85e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—PIK3CA—esophageal cancer	9.35e-06	3.83e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PIK3CA—esophageal cancer	9.34e-06	3.83e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MYC—esophageal cancer	9.29e-06	3.81e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ERBB2—esophageal cancer	9.18e-06	3.77e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1A—esophageal cancer	9.13e-06	3.74e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EGFR—esophageal cancer	9.09e-06	3.73e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTT1—esophageal cancer	8.98e-06	3.68e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EP300—esophageal cancer	8.93e-06	3.66e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP2A6—esophageal cancer	8.88e-06	3.64e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—esophageal cancer	8.87e-06	3.64e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EP300—esophageal cancer	8.68e-06	3.56e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PIK3CA—esophageal cancer	8.62e-06	3.54e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PIK3CA—esophageal cancer	8.62e-06	3.54e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1A—esophageal cancer	8.58e-06	3.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PIK3CA—esophageal cancer	8.54e-06	3.5e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ENO1—esophageal cancer	8.42e-06	3.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS1—esophageal cancer	8.42e-06	3.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.41e-06	3.45e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MYC—esophageal cancer	8.31e-06	3.41e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PSME2—esophageal cancer	8.3e-06	3.4e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PSME1—esophageal cancer	8.3e-06	3.4e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EP300—esophageal cancer	8.16e-06	3.35e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EGFR—esophageal cancer	8.13e-06	3.33e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—esophageal cancer	8.11e-06	3.33e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PIK3CA—esophageal cancer	7.89e-06	3.23e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1A—esophageal cancer	7.85e-06	3.22e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MYC—esophageal cancer	7.78e-06	3.19e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EGFR—esophageal cancer	7.61e-06	3.12e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MYC—esophageal cancer	7.57e-06	3.1e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EP300—esophageal cancer	7.47e-06	3.06e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EGFR—esophageal cancer	7.4e-06	3.03e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PIK3CA—esophageal cancer	7.22e-06	2.96e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP1B1—esophageal cancer	7.16e-06	2.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MYC—esophageal cancer	7.11e-06	2.92e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CA—esophageal cancer	7.05e-06	2.89e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EGFR—esophageal cancer	6.96e-06	2.85e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—esophageal cancer	6.82e-06	2.8e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP19A1—esophageal cancer	6.73e-06	2.76e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CA—esophageal cancer	6.6e-06	2.71e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MYC—esophageal cancer	6.51e-06	2.67e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CA—esophageal cancer	6.42e-06	2.63e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—esophageal cancer	6.39e-06	2.62e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EGFR—esophageal cancer	6.36e-06	2.61e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—esophageal cancer	6.21e-06	2.55e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HMOX1—esophageal cancer	6.14e-06	2.52e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CA—esophageal cancer	6.04e-06	2.48e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—esophageal cancer	5.84e-06	2.4e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CA—esophageal cancer	5.52e-06	2.27e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—esophageal cancer	5.34e-06	2.19e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CREBBP—esophageal cancer	3.94e-06	1.62e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NOS3—esophageal cancer	3.53e-06	1.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—esophageal cancer	3.23e-06	1.32e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—EP300—esophageal cancer	2.68e-06	1.1e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.98e-06	8.14e-06	CbGpPWpGaD
